We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Read MoreHide Full Article
Key Takeaways
Tandem Diabetes posted Q1 revenues of $247.2M, up 5.5%, beating consensus estimates.
TNDM gross margin expanded 482 bps to 55.3% as cost of sales declined 4.8%.
Tandem Diabetes reaffirmed 2026 revenue guidance of $1.065B to $1.085B.
Tandem Diabetes Care, Inc. (TNDM - Free Report) posted a first-quarter 2026 loss of 30 cents per share compared with a loss of $1.97 year ago. The figure was narrower than the Zacks Consensus Estimate of a loss of 67 cents.
TNDM’s Revenues
First-quarter worldwide revenues amounted to $247.2 million, up 5.5% year over year and 2% in constant currency. The figure surpassed the Zacks Consensus Estimate by 3.46%.
Since the earnings announcement on May 7, TNDM shares have dropped 23.6% to close at $14.11 yesterday.
TNDM’s Quarterly Performance in Detail
Tandem Diabetes reports under two primary markets based on the geographic location to which its products are shipped.
Sales in the United States totaled $160.8 million compared with $150.6 million in the prior-year period. The company shipped more than 19,000 pumps in the quarter.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
International sales increased 3% to $86.4 million compared with $83.8 million. Sales decreased 5% in constant currency. International shipments were more than 10,000 pumps.
TNDM’s Margins
The gross profit in the reported quarter was $136.8 million, up 15.5% year over year. The gross margin expanded 482 basis points (bps) to 55.3% due to a 4.8% decrease in the cost of sales.
SG&A expenses fell 5% to $108.2 million. R&D expenses increased 27.9% to $42.9 million.
The company registered an adjusted operating loss of $14.3 million compared with a loss of $29 million in the year-ago period.
Financial Position of TNDM
Tandem Diabetes exited the first quarter of 2026 with cash, cash equivalents and short-term investments of $570.3 million compared with $292.7 million at the end of 2025.
Cumulative cash provided by operating activities was $11.1 million compared with cash outflow of $21.2 million a year ago.
TNDM’s 2026 Guidance
The company continues to expect full-year sales to be approximately $1.065 billion to $1.085 billion. Within this, United States sales are projected to be roughly $730 million to $745 million, while International sales are expected between $335 million and $340 million. The Zacks Consensus Estimate for full-year revenues is projected at $1.07 billion.
Gross margin is estimated to be approximately 56% to 57% of sales. TNDM projects Adjusted EBITDA margin to be approximately 5% to 6% of sales.
Our Take
Tandem Diabetes delivered a narrower loss and revenue beat in the first quarter of 2026. Building on last year, the company achieved new first-quarter records for pump shipments, supported by U.S. performance. A key milestone in the quarter was the launch of the pay-as-you-go reimbursement model in the U.S. pharmacy channel. Expansion of gross margin is highly promising. At the same time, Tandem Diabetes is advancing several key initiatives positioning it for immediate impact and long-term growth, including modernizing its commercial operations, reshaping the business model and introducing new technologies.
TNDM’s Zacks Rank and Other Key Picks
Tandem Diabetes currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #2, reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.
LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Key Takeaways
Tandem Diabetes Care, Inc. (TNDM - Free Report) posted a first-quarter 2026 loss of 30 cents per share compared with a loss of $1.97 year ago. The figure was narrower than the Zacks Consensus Estimate of a loss of 67 cents.
TNDM’s Revenues
First-quarter worldwide revenues amounted to $247.2 million, up 5.5% year over year and 2% in constant currency. The figure surpassed the Zacks Consensus Estimate by 3.46%.
Since the earnings announcement on May 7, TNDM shares have dropped 23.6% to close at $14.11 yesterday.
TNDM’s Quarterly Performance in Detail
Tandem Diabetes reports under two primary markets based on the geographic location to which its products are shipped.
Sales in the United States totaled $160.8 million compared with $150.6 million in the prior-year period. The company shipped more than 19,000 pumps in the quarter.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart | Tandem Diabetes Care, Inc. Quote
International sales increased 3% to $86.4 million compared with $83.8 million. Sales decreased 5% in constant currency. International shipments were more than 10,000 pumps.
TNDM’s Margins
The gross profit in the reported quarter was $136.8 million, up 15.5% year over year. The gross margin expanded 482 basis points (bps) to 55.3% due to a 4.8% decrease in the cost of sales.
SG&A expenses fell 5% to $108.2 million. R&D expenses increased 27.9% to $42.9 million.
The company registered an adjusted operating loss of $14.3 million compared with a loss of $29 million in the year-ago period.
Financial Position of TNDM
Tandem Diabetes exited the first quarter of 2026 with cash, cash equivalents and short-term investments of $570.3 million compared with $292.7 million at the end of 2025.
Cumulative cash provided by operating activities was $11.1 million compared with cash outflow of $21.2 million a year ago.
TNDM’s 2026 Guidance
The company continues to expect full-year sales to be approximately $1.065 billion to $1.085 billion. Within this, United States sales are projected to be roughly $730 million to $745 million, while International sales are expected between $335 million and $340 million. The Zacks Consensus Estimate for full-year revenues is projected at $1.07 billion.
Gross margin is estimated to be approximately 56% to 57% of sales. TNDM projects Adjusted EBITDA margin to be approximately 5% to 6% of sales.
Our Take
Tandem Diabetes delivered a narrower loss and revenue beat in the first quarter of 2026. Building on last year, the company achieved new first-quarter records for pump shipments, supported by U.S. performance. A key milestone in the quarter was the launch of the pay-as-you-go reimbursement model in the U.S. pharmacy channel. Expansion of gross margin is highly promising. At the same time, Tandem Diabetes is advancing several key initiatives positioning it for immediate impact and long-term growth, including modernizing its commercial operations, reshaping the business model and introducing new technologies.
TNDM’s Zacks Rank and Other Key Picks
Tandem Diabetes currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .
BrightSpring Health Services, currently carrying a Zacks Rank #2, reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.
LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.